Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors

Trial Profile

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Everolimus (Primary) ; Lapatinib (Primary) ; Nilotinib (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary) ; Tremelimumab (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms MOST plus
  • Most Recent Events

    • 30 Aug 2018 Planned End Date changed from 1 Nov 2019 to 1 Oct 2022.
    • 30 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2020.
    • 26 Feb 2018 According to a Centre Leon Berard media release, the clinical follow-up on two of the study arms i.e the Everolimus arm targeting alterations in the PI3K/AKT/mTOR pathway, and the Sorafenib arm targeting multiple kinase proteins, has completed.Centre Leon Berard and NovellusDx are collaborating on a retrospective analysis of these two study arms.The NGS data of patients from these two arms will be analyzed blindly by the FACT system of NovellusDx to predict clinical outcome retrospectively.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top